Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Dariush Mokhtari, Nils Welsh
Clinical Science (2009) Vol. 118, Iss. 4, pp. 241-247
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents
Ian A. Clark, Bryce Vissel
Journal of Neuroinflammation (2016) Vol. 13, Iss. 1
Open Access | Times Cited: 112
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Athanasios Fountas, Leonidas Nikolaos Diamantopoulos, Agathocles Tsatsoulis
Trends in Endocrinology and Metabolism (2015) Vol. 26, Iss. 11, pp. 643-656
Closed Access | Times Cited: 88
Lost in translation: endoplasmic reticulum stress and the decline of β‐cell health in diabetes mellitus
Carmella Evans‐Molina, M. Hatanaka, Raghavendra G. Mirmira
Diabetes Obesity and Metabolism (2013) Vol. 15, Iss. s3, pp. 159-169
Open Access | Times Cited: 57
Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature
Dominika Labochka, Barbara Moszczuk, Wojciech Kukwa, et al.
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 6, pp. 1887-1894
Open Access | Times Cited: 37
Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity
Ramona Steri, Janosch Achenbach, Dieter Steinhilber, et al.
Biochemical Pharmacology (2012) Vol. 83, Iss. 12, pp. 1674-1681
Closed Access | Times Cited: 36
Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5′-phosphatase interaction with c-Abl
Dariush Mokhtari, Rasel A. Al-Amin, Kyril Turpaev, et al.
Diabetologia (2013) Vol. 56, Iss. 6, pp. 1327-1338
Open Access | Times Cited: 33
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index
Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, et al.
Leukemia Research (2012) Vol. 36, Iss. 4, pp. e66-e67
Closed Access | Times Cited: 27
RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice
Brittany M. Duggan, Joseph F. Cavallari, Kevin P. Foley, et al.
Endocrinology (2020) Vol. 161, Iss. 8
Open Access | Times Cited: 19
Advances in Pancreatic Neuroendocrine Tumor Treatment
Daniel Castellano, Enrique Grande, Jorge Barriuso
New England Journal of Medicine (2011) Vol. 364, Iss. 19, pp. 1871-1875
Closed Access | Times Cited: 24
Effects of Imatinib Mesylate (Gleevec) on Human Islet NF-kappaB Activation and Chemokine Production In Vitro
Dariush Mokhtari, Tingting Li, Tao Lu, et al.
PLoS ONE (2011) Vol. 6, Iss. 9, pp. e24831-e24831
Open Access | Times Cited: 22
Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells
Rikard G. Fred, Santosh Kumar Boddeti, Marcus Lundberg, et al.
Clinical Science (2014) Vol. 128, Iss. 1, pp. 17-28
Closed Access | Times Cited: 21
Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats
Eri Mukai, Takeshi Ohta, Harukiyo Kawamura, et al.
Diabetes Research and Clinical Practice (2014) Vol. 106, Iss. 2, pp. 303-311
Closed Access | Times Cited: 21
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
Miguel Ángel Gómez-Sámano, Jorge Baquerizo‐Burgos, Marı́a Florencia Coronel, et al.
BMC Endocrine Disorders (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 20
The Tyrphostin Agent AG490 Prevents and Reverses Type 1 Diabetes in NOD Mice
Abdoreza Davoodi‐Semiromi, Clive Wasserfall, Chang Xia, et al.
PLoS ONE (2012) Vol. 7, Iss. 5, pp. e36079-e36079
Open Access | Times Cited: 20
Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A case report
Yenna Lee, Hye Seung Jung, Hyung Jin Choi, et al.
Diabetes Research and Clinical Practice (2011) Vol. 93, Iss. 2, pp. e68-e70
Closed Access | Times Cited: 20
Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca2+/calmodulin-dependent protein kinase IIα (Thr286Asp) transgenic mice
Hikari Suzuki, Isao Usui, I. Kato, et al.
Diabetologia (2011) Vol. 54, Iss. 11, pp. 2953-2962
Open Access | Times Cited: 19
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes
Adriano Salaroli, Giuseppina Loglisci, Alessandra Serrao, et al.
Annals of Hematology (2012) Vol. 91, Iss. 11, pp. 1823-1824
Closed Access | Times Cited: 17
New approaches to the treatment of nephropathy in diabetes
Merlin C. Thomas, Per‐Henrik Groop
Expert Opinion on Investigational Drugs (2011) Vol. 20, Iss. 8, pp. 1057-1071
Closed Access | Times Cited: 16
Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
Jung Hun Ohn, Yeong Gi Kim, Se‐Hoon Lee, et al.
Endocrinology and Metabolism (2013) Vol. 28, Iss. 2, pp. 149-149
Open Access | Times Cited: 15
Small‐molecule inhibition of inflammatory β‐cell death
Morten Lundh, Stephen S. Scully, Thomas Mandrup‐Poulsen, et al.
Diabetes Obesity and Metabolism (2013) Vol. 15, Iss. s3, pp. 176-184
Open Access | Times Cited: 15
Tyrphostin AG490 Agent Modestly but Significantly Prevents Onset of Type 1 in NOD Mouse; Implication of Immunologic and Metabolic Effects of a Jak-Stat Pathway Inhibitor
Abdoreza Davoodi‐Semiromi, Azadeh Hassanzadeh, Clive Wasserfall, et al.
Journal of Clinical Immunology (2012) Vol. 32, Iss. 5, pp. 1038-1047
Closed Access | Times Cited: 15
FAM3D: A gut secreted protein and its potential in the regulation of glucose metabolism
Caroline Moser, Katherine Gosselé, Miroslav Baláž, et al.
Peptides (2023) Vol. 167, pp. 171047-171047
Open Access | Times Cited: 4
Erlotinib appears to produce prolonged remission of insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease
Marvin B. Brooks
The British Journal of Diabetes (2012) Vol. 12, Iss. 2, pp. 87-90
Closed Access | Times Cited: 12
Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes
Zhihong Huang, Matthew S. Tremblay, Tom Wu, et al.
ACS Omega (2019) Vol. 4, Iss. 2, pp. 3571-3581
Open Access | Times Cited: 11
Does the small tyrosine kinase inhibitor imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?
Nils Welsh
Expert Opinion on Investigational Drugs (2012) Vol. 21, Iss. 11, pp. 1743-1750
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top